0.01Open0.05Pre Close27 Volume338 Open Interest5.00Strike Price41.00Turnover188.17%IV26.63%PremiumApr 11, 2025Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.1214Delta0.2800Gamma99.50Leverage Ratio-0.0202Theta0.0000Rho12.08Eff Leverage0.0008Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet